AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05329233 — intervention group
Intervention type: DEVICE
Intervention: Masimo Radical-7 Pulse CO-Oximeter
Description: The Masimo Radical-7 Pulse CO-Oximeter is a device for the measurement of pulse oximetry, oxygen reserve index (ORi), perfusion index (PI), and pleth variability index (PVI). The device is the product of a company called Masimo Inc, Irvine, CA, USA
Study NCT05051423 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic ultrasound
Description: Imaging tests:~All patients will be evaluated by EUS and CEH-EUS, using radial EUS instruments. Prior to the investigation the stomach has to be empty for at least 8 hours. During the examination biopsies will be taken from normal and tumor tissue for gene expression analysis.~CEH-EUS procedure:~A two panel image with the usual conventional gray-scale B-mode EUS image on the right side and with the contrast harmonic image on the left side will be used, according to pre-established presets. The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 2,4 mL), with the whole movie (T0-T120s) recorded on the embedded HDD of the ultrasound system for later analysis~Molecular tests:~Blood analysis. Whole blood (1ml) will be collected before imaging procedures in an Eppendorf tube on EDTA solution.~Biopsy samples of normal and GC tissue. Gene expression will be analyzed using qPCR with Taqman®- labeled probes.
Study NCT03927690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LKA651
Description: LKA651 5 mg Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
Study NCT03927690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: Lucentis 0.3 mg (U.S. sites) or 0.5 mg (ex U.S. sites) Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
Study NCT03927690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: Lucentis 0.3 mg (U.S. sites) or 0.5 mg (ex U.S. sites) Intravitreal injection, every 4 weeks for 12 weeks in the treatment phase
Study NCT01850823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01850823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Nasal Spray
Study NCT01850823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone nasal spray
Study NCT00715637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin and Cytarabine
Description: Daunorubicin: 45 mg/m2 over 30 minutes daily on days 1-3 (up to max. of 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on days 1-7 (up to max. of 2 courses)
Study NCT00715637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amonafide and Cytarabine
Description: Amonafide: 600 mg/m2 IV over 4 hours daily on Days 1-5 (up to max. 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on Days 1-7 (up to max. 2 courses)
Study NCT01605656 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive Interview
Description: A research staff member will use a questionnaire to ask about many different health and social topics. The cognitive interview should take up to 45 minutes to complete.
Study NCT01605656 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Phase I: Completion of a questionnaire about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~Phase II: Completion of 2 questionnaires. The first questionnaire will ask about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~The second questionnaire will ask about many different health and social topics. This questionnaire should take up to 45 minutes to complete.
Study NCT01605656 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Groups
Description: Phase I: There will be up to 8 women in each of the 5 focus groups.~Participants asked questions about personal and clinic-related factors that might make it more difficult to receive pap smear screenings. Participants also asked to discuss what might make it easier or encourage women to receive pap smear screenings. The focus group discussion should last 60-90 minutes.
Study NCT01785147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1.4979
Description: BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.
Study NCT01785147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04137718 — intervention group
Intervention type: OTHER
Intervention: nonIntervention
Description: nonIntervention
Study NCT04853134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proxalutamide
Description: 200 mg q.d.
Study NCT04853134 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of care as determined by the PI
Study NCT01649505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fibrin sealant (Beriplast P, TISSEEL VH)
Description: Applied topically
Study NCT01649505 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: breast reconstruction
Description: Undergo sharp dissection technique
Study NCT01649505 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: breast reconstruction
Description: Undergo electrocoagulation dissection technique
Study NCT00188825 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00188825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basiliximab
Study NCT01397500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin
Description: Genotropin administered sc once a day by patient or caregiver.
Study NCT01397500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone undecannoate
Description: Testosterone undecannoate administered twice (6 week Interval) im by investigator.
Study NCT01579721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Incision Laparoscopic Surgery
Description: Single incision laparoscopic surgery for rectal cancer
Study NCT00610025 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transgastric access to the abdomen
Description: Upper endoscopy, gastrotomy created with a needle knife followed by lower endoscopy.
Study NCT03588819 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: 26 Gy in 2 fractions to the prostate and DIL dose of up to 32 Gy in 2 fractions of MR-guided SABR delivered 1 week apart
Study NCT03694626 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pupillography
Description: A hand-held pupillometer/electroretinogram device (RETeval, LKC) will be held in front of the subject's eye, but will not touch the eye. The device will provide a brief, a series of brief light stimuli and then record the pupil response and the elicited electrical response from the retina from a surface skin patch (electrode) placed below each eye, from the light as a measure of whether the inherent sensitivity of the eye in the retina is normal. The investigators will repeat this in the left eye. The visible light stimulus is safe and is given at an intensity experienced in normal daily light exposures. The test takes about 2 minutes per eye.
Study NCT03694626 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ocular Coherence Tomography (OCT)
Description: The thickness of the optic nerve and macula will also be measured inside of the eye using a special camera that forms an image of the layers of the retina without pupil dilation. The imaging is harmless and measures the structural health of the optic nerve and retinal layers. This test takes 5-10 minutes per eye.
Study NCT03694626 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wrist-watch sensor device
Description: A wrist-watch sensor device (E4, Empatica) will be place on each wrist to measure skin conductance, heart rate, skin temperature and arm movement during testing. These wrist-watch devices are being used to monitor changes in sympathetic nerve activity to light intensity, (the sympathetic nerves supply the blood vessels to the skin and heart).
Study NCT03694626 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Videography
Description: The subject will sit comfortably in front of miniature combination infrared/visible light video cameras and infrared diode light source located within 1 meter to provide video recording of the face during testing with light and during darkness, described next.~After the 10 minutes of dark-adapting, the subject will put his/her chin on a chin rest in front of the video cameras and a light emitting diode (LED) array give diffuse red, blue, and white stimuli over a range of intensities. None of the stimuli are as bright as a flash from a camera and are in the range of intensities normally experienced during daily activities.~At the end of the test the investigators will add filters over the glasses: orange (blue-blocking) filters and neutral density filters. Subjects will grade independently, both the brightness and discomfort they feel from each light stimulus intensity.
Study NCT03694626 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrophysiology
Description: Next, electrodes will be placed above, below and to the side of the test eye to record the electromyogram (EMG) for measuring eyelid opening and blink rate.
Study NCT01743521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV/PEG-IFN/RBV
Description: Drug Telaprevir (TPV): dosed 1125mg twice daily (given as three 375 mg film-coated tablets) orally, except in the situation where a patient is on efavirenz in which case the dose of telaprevir will be 1125mg three times daily.~Drug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg).~Drug PEG-IFN (other name: Pegasys): 180mcg in 0.5ml (pre-filled syringes) administered subcutaneously once weekly.
Study NCT03080662 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ORYGEN DUAL Sham Valve
Description: Training of the inspiratory muscles during 5 weeks
Study NCT03080662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORYGEN DUAL Valve
Description: Training of the inspiratory muscles during 5 weeks
Study NCT00611715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: OSI-774 150 mg/day
Study NCT00611715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole 2.5 mg/day
Study NCT00611715 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: To determine HER2 gene amplification or excess copies of the HER2 gene
Study NCT00611715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: to measure the epidermal growth factor receptors (EGFR)
Study NCT00611715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: To determine if specific biomarkers exhibit a longer time to tumor progression after treatment with the study drugs
Study NCT02137577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DEB catheter
Description: DEB catheter (trade name: Litos/Tulip)
Study NCT02137577 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: common PTA balloon catheter
Description: common PTA balloon catheter
Study NCT01016418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine colostrum powder
Description: Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
Study NCT03510806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplement
Description: dietary supplement contain protein from milk and fruit extract
Study NCT03510806 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: color, taste, and calorie-matched placebo
Study NCT00595647 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug eluting stent
Description: Implantation of stent
Study NCT00595647 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bare metal stent
Description: Implantation of stent
Study NCT03783858 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: P200TE
Description: OCT images
Study NCT02259062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music with brief mindfulness intervention
Description: Music listening with mindfulness therapy
Study NCT02259062 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music listening alone
Study NCT02259062 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Audiobook listening
Study NCT04191148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBP-EC01
Description: crPhage cocktail: at approximately 1.5 x 10\^10 to 3.0 x 10\^10 PFU/vial dosed BID by intraurethral administration
Study NCT04191148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactated Ringers Solution for Injection dosed BID by intraurethral administration
Study NCT00345800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate (Xyrem)
Description: * Active Substance: Sodium Oxybate~* Pharmaceutical form: Oral Solution~* Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks~* Route of administration: Oral
Study NCT01470729 — intervention group
Intervention type: OTHER
Intervention: metabolic and imaging biomarkers in SCA1,2,3 and 7 patients
Description: MRI, a bone mineral density and a resting metabolic rate assessments, as well as donating fasted blood samples
Study NCT00078728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based Anxiety Prevention Program
Description: Participants in the prevention program will have weekly sessions with a therapist and will learn skills to help reduce anxiety for 8 weeks. The intervention will begin immediately after randomization to the study.
Study NCT00078728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation only
Description: Participants will undergo evaluations without active treatment for 8 weeks.
Study NCT01325597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined training
Description: FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks. The IMT will also be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure.
Study NCT01325597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks
Study NCT01325597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: IMT will be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure
Study NCT01325597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: No intervention
Study NCT02726035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: oral naltrexone 50 mg daily
Study NCT02726035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral placebo (appearing identical to naltrexone) once daily
Study NCT03723122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Communication Reinforcement Intervention
Description: Psycho-educative and behavioral intervention centered on cancer-related dyadic communication
Study NCT03740477 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: Eligible participants will receive a 30-second ECG recording during their visit at the Absentee Shawnee Tribal clinic
Study NCT00913068 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverse Abdominal Plan (TAP)
Description: An injectable anesthetic is introduced to a specific anatomic area where the sensory neurons supplying the operative field.
Study NCT00913068 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard post op pain control
Description: opiates
Study NCT03121495 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Second forward view (SFV) examination of the right colon
Description: The colonoscope will be advanced to the cecum again when hepatic flexure was reached the first time, where a second forward view (SFV) examination of the right colon will be performed
Study NCT02107742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal speed lidocaine injection
Description: 30 seconds
Study NCT02107742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Slow lidocaine injection
Description: speed 45 seconds
Study NCT02107742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast lidocaine injection
Description: speed 15 seconds
Study NCT01799109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate & albuterol
Study NCT01799109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol
Study NCT01799109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium
Study NCT01849445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intensive physiotherapy
Description: Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.
Study NCT01849445 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home physiotherapy exercises
Description: Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
Study NCT02282306 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TTIP-PRO
Description: The peer-delivered TTIP-PRO intervention is designed to: 1). increase the patient's knowledge of risk factors for OOD, with a particular emphasis on the patient's personal risk factors. This aim is one of harm reduction and is intended to help patients who continue to abuse opioids to use in a safer manner and 2).For patients who are open to considering treatment, to encourage the patient to get treatment for his/her opioid use disorder. This goal is based on research findings that effective treatment reduces the risk of OOD.
Study NCT03493568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genvoya 150Mg-150Mg-200Mg-10Mg Tablet
Description: switch to Genvoya 150Mg-150Mg-200Mg-10Mg Tablet in patients virologically suppressed HIV-1 infected patients.
Study NCT03493568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir 50 mg plus one RTI
Description: Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)
Study NCT00644956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: tadalafil 20 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
Study NCT00644956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil
Description: sildenafil 100 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
Study NCT01340300 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Two supervised exercise sessions per week
Study NCT01340300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral metformin QD for two weeks, then BID
Study NCT01340300 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational information
Description: educational information
Study NCT02208037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (ARM with Methotrexate)
Description: Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels. The dose should be adjusted accordingly to maintain a suggested level of 5-15 ng/mL. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
Study NCT02208037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (ARM with MMF and Cyclophosphamide)
Description: Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day +5. Serum levels of tacrolimus will be measured at Day 7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.